Date: 2011-02-22
Type of information: Development agreement
Compound: Clinical development services
Company: Pierrel Research International (Germany-Italy)Siena Biotech (Italy)
Therapeutic area: Neurodegenerative diseases - Cancer - Oncology
Type agreement: development
Action mechanism:
Disease:
Details: Pierrel Research International AG, a subsidiary of the italian group Pierrel, and Siena Biotech have entered into a framework agreement to cooperate in the clinical development of Phases I and II, of innovative molecules, that are the result of Siena Biotech research. Such agreement foresees Pierrel Research as the preferential partner for the development of the investigational drugs of Siena Biotech. Pierrel Research will make available to Siena Biotech all the necessary resources, duly, organized and adapted to the specific needs of each clinical study that has been assigned to it. Furthermore, Pierrel Research will have the option to select those molecules/therapeutic indications proposed by Siena Biotech, which it considers interesting for an alliance model, and on which, following exhaustive pharmacological, toxicological, clinical and regulatory evaluation, and assessment of the business potential, including an analysis of the competitive scenario, carried out by its team of international experts, it may decide to co-invest, according to the terms that will be defined on per project basis.
Financial terms: Financial details were not disclosed,
Latest news:
